Michael Becker to Uric Acid
This is a "connection" page, showing publications Michael Becker has written about Uric Acid.
Connection Strength
3.807
-
An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct; 45(2):174-83.
Score: 0.504
-
Urate transporters: transforming the face of hyperuricemia and gout. J Rheumatol. 2014 Oct; 41(10):1910-2.
Score: 0.480
-
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2):R63.
Score: 0.354
-
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009 Jun; 36(6):1273-82.
Score: 0.328
-
Crystal-induced arthropathies: recent investigative advances. Curr Opin Rheumatol. 2006 May; 18(3):249-55.
Score: 0.269
-
Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids. 2004 Oct; 23(8-9):1111-6.
Score: 0.241
-
Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013 Sep 01; 72(9):1469-74.
Score: 0.106
-
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011 Dec; 30(12):1011-7.
Score: 0.099
-
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17; 306(7):711-20.
Score: 0.097
-
Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology? J Rheumatol. 2011 Jul; 38(7):1462-6.
Score: 0.096
-
What do I need to know about gout? J Fam Pract. 2010 Jun; 59(6 Suppl):S1-8.
Score: 0.089
-
Update on emerging urate-lowering therapies. Curr Opin Rheumatol. 2009 Mar; 21(2):143-9.
Score: 0.082
-
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008 Nov 15; 59(11):1540-8.
Score: 0.080
-
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008 Sep; 58(9):2882-91.
Score: 0.079
-
Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness. Am J Med. 1988 Sep; 85(3):383-90.
Score: 0.079
-
Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). Rheum Dis Clin North Am. 1988 Aug; 14(2):377-94.
Score: 0.079
-
We can make gout management more successful now. Curr Opin Rheumatol. 2008 Mar; 20(2):167-72.
Score: 0.076
-
Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006; 8 Suppl 1:S4.
Score: 0.067
-
Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005 Dec 08; 353(23):2450-61.
Score: 0.066
-
Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol. 2005 Dec; 32(12):2368-72.
Score: 0.065
-
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005 Mar; 52(3):916-23.
Score: 0.062
-
Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman. Arthritis Rheum. 2003 Jul; 48(7):2036-41.
Score: 0.055
-
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. Arthritis Rheumatol. 2022 09; 74(9):1593-1601.
Score: 0.052
-
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Arthritis Rheumatol. 2019 01; 71(1):143-153.
Score: 0.041
-
Fibroblast phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in gout with purine overproduction. Adv Exp Med Biol. 1977; 76A:270-9.
Score: 0.035
-
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014 Dec; 20(8):427-32.
Score: 0.031
-
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013 Sep 26; 15(5):R137.
Score: 0.028
-
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb; 64(2):256-61.
Score: 0.025
-
Identification of distinct PRS1 mutations in two patients with X-linked phosphoribosylpyrophosphate synthetase superactivity. Adv Exp Med Biol. 1991; 309B:125-8.
Score: 0.023
-
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009 Feb; 48(2):188-94.
Score: 0.020
-
Diagnostic evaluation of phosphoribosylpyrophosphate synthetase activities in hemolysates. J Lab Clin Med. 1984 Jun; 103(6):932-43.
Score: 0.015
-
Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate. J Lab Clin Med. 1982 Apr; 99(4):495-511.
Score: 0.013
-
Variant human phosphoribosylpyrophosphate synthetase altered in regulatory and catalytic functions. J Clin Invest. 1980 Jan; 65(1):109-20.
Score: 0.011
-
Uricosuric effects of niridazole. Clin Pharmacol Ther. 1977 Nov; 22(5 Pt 1):568-72.
Score: 0.009
-
Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in fibroblasts from patients with gout and purine overproduction. J Clin Invest. 1976 Feb; 57(2):308-18.
Score: 0.008
-
Evaluation of the role of 5-phosphoribosyl-alpha-1-pyrophosphate synthetase in congenital hyperuricemia and gout: a simple isotopic assay and an activity stain for the enzyme. Biochem Med. 1974 Jul; 10(3):266-75.
Score: 0.007
-
Genetic aspects of gout. Annu Rev Med. 1974; 25(0):15-28.
Score: 0.007
-
Gout with purine overproduction due to increased phosphoribosylpyrophosphate synthetase activity. Am J Med. 1973 Aug; 55(2):232-42.
Score: 0.007
-
Purine overproduction in man associated with increased phosphoribosylpyrophosphate synthetase activity. Science. 1973 Mar 16; 179(4078):1123-6.
Score: 0.007
-
Increased PP-ribose-P synthetase activity: a genetic abnormality leading to excessive purine production and gout. Adv Exp Med Biol. 1973; 41:307-15.
Score: 0.007
-
Increased purine nucleotide degradation in the central nervous system (CNS) in PRPP synthetase superactivity. Adv Exp Med Biol. 1989; 253A:9-13.
Score: 0.005